Roivant Sciences' subsidiary Genevant Sciences and Arbutus Biopharma filed three new patent infringement lawsuits against Pfizer and BioNTech. These filings in Canada and Europe’s Unified Patent Court target the Comirnaty COVID-19 vaccine.
The plaintiffs allege the vaccine unlawfully uses their proprietary lipid nanoparticle (LNP) delivery technology. This action expands an existing U.S. legal battle involving five related patents.
Genevant and Arbutus seek monetary damages and injunctions to stop the alleged infringement. The move follows a multi-billion dollar settlement with Moderna that validated the technology's patent value.